Impact of EDP-M on survival of patients with metastatic adrenocortical carcinoma: A population-based study
European Journal of Cancer · 2024
DOI: 10.1016/j.ejca.2023.113424 ↗Kurz gefasst
Fachartikel in der Zeitschrift European Journal of Cancer, 2024. Verfasst von Pien Debets und 8 weiteren Autor:innen. Beteiligte Einrichtung: Amsterdam UMC location VU Medical Center, department of Medical Oncology, Amsterdam, the Netherlands. Hauptthemen laut MEDLINE: Adrenocortical Carcinoma, Adrenal Cortex Neoplasms. Die Arbeit wurde bisher 20-mal zitiert (Crossref) und nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
INTRODUCTION: Historically, stage IV adrenocortical carcinoma (mACC) has a poor prognosis with a median overall survival (OS) of only 5 months. Based on the FIRM-ACT trial published in 2012, guidelines now advise first line systemic treatment with etoposide, cisplatin, doxorubicin and mitotane (EDP-M). The effect of EDP-M on patient survival in clinical practice in the Netherlands is unknown. METHODS: The data of all patients with mACC (2005-2020) were obtained from the Netherlands comprehensive cancer organization (IKNL). The effect of EDP-M on patient survival was assessed using Kaplan-Meier analysis and multivariate Cox regression analysis including clinical, therapy and tumor characteristics. RESULTS: In total 167 patients with mACC were included. For patients diagnosed from 2014 onwards, EDP-M (in 22 patients (22%)) lead to a numerically but not statistically significant improved OS compared to those not receiving EDP-M (11.8 vs 5.6 months, p = 0.525). For systemic treatments, patients treated with mitotane only had the best 5-year OS (11.4%, p = 0.006) regardless of year of diagnosis. In multivariate Cox regression analysis EPD-M was not associated with OS; palliative adrenalectomy (HR: 0.26, p = 20% (HR: 2.67, p = 0.003) with a worse OS from 2014 onwards. Patients diagnosed before 2014 had a significantly poorer OS compared to from 2014 onwards (5-yr: 4.5 vs 8.4%, OS: 6.8 vs 8.3 months, p = 0.032). CONCLUSION: OS for mACC in the Netherlands has improved in the last decade. Receiving EDP-M did not significantly improve OS for patients with mACC. The use of multimodality treatment including palliative adrenalectomy, mitotane and local treatment of (oligo-)metastases in appropriately selected patients has improved the OS for mACC patients since 2014.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Amsterdam UMC location VU Medical Center, department of Medical Oncology, Amsterdam, the Netherlands.
- Amsterdam UMC location VU Medical Center, department of Endocrinology and Metabolism, Amsterdam, the Netherlands; Cancer Center Amsterdam, the Netherlands.
- Amsterdam UMC location VU Medical Center, department of Surgery, Amsterdam, the Netherlands.
- Amsterdam UMC location VU Medical Center, Department of Radiation Oncology and Cancer Center Amsterdam, Amsterdam, the Netherlands.
- Maxima Medical Center, department of Internal Medicine, Eindhoven, the Netherlands; Maastricht University, CAPHRI School for Public Health and Primary Care, Ageing and Long-Term Care, Maastricht, the Netherlands; Depart…
- Maxima Medical Center, department of Internal Medicine, Eindhoven, the Netherlands; Maastricht University, CAPHRI School for Public Health and Primary Care, Ageing and Long-Term Care, Maastricht, the Netherlands; Nether…
Zitieren
APA
Debets, P., Dreijerink, K. M. A., Engelsman, A., Dahele, M., Haak, H. R., Steenaard, R. V., Kapiteijn, E., Corssmit, E., & Menke-van der Houven van Oordt, C. W. (2024). Impact of EDP-M on survival of patients with metastatic adrenocortical carcinoma: A population-based study. European Journal of Cancer. https://doi.org/10.1016/j.ejca.2023.113424
Vancouver
Debets P, Dreijerink KMA, Engelsman A, Dahele M, Haak HR, Steenaard RV, et al. Impact of EDP-M on survival of patients with metastatic adrenocortical carcinoma: A population-based study. European Journal of Cancer. 2024. doi:10.1016/j.ejca.2023.113424
BibTeX
@article{Debets2024,
author = {Debets, Pien and Dreijerink, Koen M A and Engelsman, Anton and Dahele, Max and Haak, Harm R and Steenaard, Rebecca V and Kapiteijn, Ellen and Corssmit, Eleonora and Menke-van der Houven van Oordt, C Willemien},
title = {Impact of EDP-M on survival of patients with metastatic adrenocortical carcinoma: A population-based study},
journal = {European Journal of Cancer},
year = {2024},
doi = {10.1016/j.ejca.2023.113424}
}
EUVIMED